MAP2K7 and non-small cell lung carcinoma: In a patient suffering from an EGFR-mutant NSCLC with BRAF V600E mutation as an ARM to osimertinib, we observed that the EGFR/BRAF/MEK pathway co-inhibition with dabrafenib, trametinib plus osimertinib triple therapy (as suggested in Figure 1) was more effective than the dabrafenib plus trametinib dual therapy [25].